Search
Displaying 161–170 of 1085 results
-
Beacon Stories
In her almost eighth decade of life, Toni Mehler has learned to adapt to the unknown, and she draws from those experiences to embrace her diagnosis of AMD.
-
Beacon Doses First Patient in its Phase 2/3 VISTA Clinical Trial for XLRP Gene Therapy
Research NewsThe company plans to apply for regulatory approval for the gene therapy with data from VISTA and its earlier clinical trials.
-
The Cincy Source provides a platform for professionals serving the blind and low vision community in Cincinnati and surrounding areas to showcase services and other resources.
-
The First Coast Family Coalition provides a platform for professionals serving the blind and low vision community in Jacksonville and surrounding areas to showcase services and other resources.
-
The Philly Phorum provides a platform for professionals serving the blind and low vision community in Philadelphia and surrounding areas to showcase services and other resources.
-
Foundation Forums for Blindness
The Foundation Forums for Blindness is a network of professionals serving the blind and low vision community in markets all over the U.S.
-
Eye on the Cure Podcast | Episode 67: Dr. Peter Campochiaro
Eye on the CureDr. Peter Campochiaro, a clinician-scientist and the Eccles Professor of Ophthalmology and Neuroscience at the Johns Hopkins University School of Medicine, talks to host Ben Shaberman about N-acetylcysteine (NAC), a drug that shows promise for preserving cone vision (central vision and acuity) in people with retinitis pigmentosa. The powerful antioxidant has moved into a 30+ site, Phase 3 clinical trial called NAC Attack.
-
Antabuse Moves into Clinical Trial for People with RP
Research NewsResearchers believe the FDA-approved drug can reduce the hyperactivity of ganglion cells to improve vision.
-
GoodMaps and Be My Eyes.
-
Eye on the Cure Podcast | Episode 66: Peter Wallsten
Eye on the CurePeter Wallsten, a veteran newspaper journalist and head of investigative reporting at The Washington Post, talks to host Ben Shaberman.
